Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
The value of priority review vouchers, which drugmakers can use to expedite U.S. FDA review of their products, seems to be dwindling. Kyowa Hakko Kirin and Ultragenyx Pharmaceutical recently sold a priority review voucher for $80.6 million to an undisclosed buyer. That’s half the average value that nine previous vouchers sold for. FDA awards the vouchers to companies that develop a drug for a neglected disease. The partners got it for Crysvita, which FDA approved in April to treat a rare form of rickets.
This article has been sent to the following recipient: